Professor Jolanda de Vries is head of the Department of Tumor Immunology at the Radboud Institute for Molecular Life Sciences. Her main focus of research is on dendritic cell (DC) biology and on translational immunology. She belongs to the pioneers that translated dendritic cell biology into clinical practice. The first clinical phase I/II studies in which cancer patients were vaccinated with DC loaded with tumor-specific peptides date back to 1997. Along these early clinical trials she also developed novel immuno-monitoring tools that are highly predictive for extended survival after vaccination with DC (J Clin Oncology 2005). Similarly, she developed novel imaging tools to image the migration of DC in vivo by MRI (Nature Biotechnology 2005), or to measure antigen specific T cells responses in vivo by PET imaging (PNAS 2011). Her current work is focused on the biology and clinical use of DC that naturally occur in the blood. This has led to a randomised phase III trial with plasmacytoid DC and myeloid cDC2.